8-K: Nocera Secures $3.15M in Preferred Stock Sale

Nocera, Inc. has entered into a Securities Purchase Agreement with an institutional investor to sell up to 13,500 shares of Series B Convertible Non-Voting Preferred Stock, raising $3.15 million in an initial closing.

Summary

• Nocera, Inc. (NCRA) entered a Securities Purchase Agreement on August 29, 2025, with an institutional accredited investor.
• The agreement involves the sale of up to 13,500 shares of newly-designated Series B Convertible Non-Voting Preferred Stock, each with a stated value of $1,000, at a purchase price of $910 per share.
• An initial closing on August 29, 2025, saw the issuance and sale of 3,500 shares of Series B Preferred Stock for an aggregate purchase price of $3.15 million.
• The company may issue and sell up to an additional 10,000 shares of Series B Preferred Stock in subsequent closings.
• The Series B Preferred Stock is convertible into common stock at a conversion price of $1.80, subject to adjustments and a beneficial ownership limitation (4.99% or 9.99% upon election).
• Holders of Series B Preferred Stock will receive a mandatory monthly dividend at an annual rate of 9.0% of the aggregate stated value, payable in cash or common stock, starting October 1, 2025.
• The Series B Preferred Stock ranks senior to Common Stock and Series A Preferred Stock regarding dividends, distributions, and liquidation.
• The company is required to seek stockholder approval for the full issuance of conversion shares within 60 calendar days of the initial closing.
• A Registration Rights Agreement was also executed, obligating the company to register the resale of the common stock underlying the Series B Preferred Stock.

Sentiment

Score: 6

Explanation: The capital raise provides much-needed working capital and strategic flexibility, which is positive. However, the high dividend rate, potential for significant dilution, and numerous mandatory redemption triggers (especially those tied to stock price and market cap) introduce considerable financial risk and obligations for the company. The discount on the preferred stock purchase price also suggests a less favorable financing environment.

Positives

• Secured $3.15 million in capital from an institutional investor at the initial closing, with potential for additional funding up to 10,000 shares.
• The Series B Preferred Stock is non-voting, preventing immediate dilution of voting control for existing common stockholders.
• The company retains the option to redeem the Series B Preferred Stock at any time, providing flexibility in managing its capital structure.
• The capital infusion is designated for general corporate purposes and working capital, supporting ongoing operations and growth initiatives.

Negatives

• The Series B Preferred Stock carries a high mandatory monthly dividend rate of 9.0% annually, which could be a significant ongoing cash outflow or lead to substantial common stock dilution if paid in shares.
• The purchase price of $910 per share for stock with a $1,000 stated value implies a discount, potentially reflecting the company's funding needs or perceived risk.
• The company is restricted from issuing certain other equity or equity-linked securities (Variable Rate Transactions) during the Covenant Period without investor consent, limiting future financing flexibility.
• Numerous 'Mandatory Redemption Events' could force the company to repurchase the Series B Preferred Stock at a premium (125% of stated value plus accrued dividends) under adverse conditions, such as a significant drop in stock price or a Material Adverse Effect.
• Failure to obtain stockholder approval for the full issuance of conversion shares by the Stockholder Meeting Deadline (60 days post-closing) or maintain an effective registration statement could trigger mandatory redemption events and financial penalties.
• The conversion price of $1.80, while subject to adjustment, could lead to significant dilution if the common stock trades below this price and conversions occur at the lower 'Market Price'.

Risks

• Dilution Risk: Conversion of Series B Preferred Stock into common stock, especially at a lower 'Market Price' or if dividends are paid in stock, could significantly dilute existing common stockholders.
• High Dividend Obligation: The mandatory 9.0% annual dividend on the Series B Preferred Stock creates a substantial financial obligation that could strain cash flow or lead to further equity dilution.
• Mandatory Redemption Events: Various events, including failure to pay dividends, material breach of agreements, default on other indebtedness exceeding $300,000, bankruptcy, a Material Adverse Effect, failure to maintain an effective registration statement, trading suspension, conversion failures, failure to remove restrictive legends, failure to obtain stockholder approval, a 'Floor Price Event' (common stock below $0.30 for 3 days in 10), 'Equity Condition Failures' (market capitalization below $5 million for 5 days in 7), or a Change of Control/Fundamental Transaction, could trigger mandatory redemption at a premium (125% of stated value plus accrued dividends).
• Financing Restrictions: Covenants restrict the company from issuing certain types of equity or equity-linked securities (Variable Rate Transactions) and other Series B Preferred Stock without investor consent, potentially limiting future capital-raising options.
• Nasdaq Listing Rule Compliance: Failure to obtain stockholder approval for the full issuance of conversion shares in accordance with Nasdaq Listing Rule 5635(d) could lead to non-compliance and further penalties or mandatory redemption.
• Registration Statement Failures: Failure to timely file or maintain the effectiveness of the registration statement for the resale of Conversion Shares, or a 'Current Public Information Failure,' will result in 'Registration Delay Payments' to investors.
• Market Price Volatility: The conversion rate and redemption prices are tied to the common stock's market price, exposing the company to volatility and potentially increasing the cost of conversion or redemption.

Future Outlook

The company plans to use the net proceeds from the sale of Series B Preferred Stock for general corporate purposes and working capital. It is committed to obtaining stockholder approval for the full issuance of the underlying common shares within 60 calendar days of the initial closing and will file a registration statement to allow for the resale of these shares by the investor. The company also aims to maintain its Nasdaq listing and comply with all associated rules.

Industry Context

This capital raise through convertible preferred stock is a common strategy for public companies, particularly those that may need to bolster working capital or fund strategic initiatives without immediately diluting common shareholders' voting power. The terms, including a high dividend rate and various mandatory redemption triggers tied to financial performance and stock price, suggest a financing arrangement typical for companies seeking capital under specific market conditions or with certain risk profiles, often seen in smaller-cap or growth-oriented sectors.

Corporate Governance

Stakeholder Impact

• Shareholders (Common Stock): Potential for significant dilution upon conversion of Series B Preferred Stock, especially if the common stock price is low. Their claims on assets and dividends are subordinated to Series B holders. Voting power is not immediately diluted by the Series B shares themselves, but future stockholder approval is required for full conversion.
• Investors (Series B Preferred Stock): Receive a high mandatory monthly dividend (9.0% annually) and have senior ranking in liquidation. They have strong protective provisions, including mandatory redemption triggers and anti-dilution rights, but face the risk of the company's financial distress triggering these events.
• Employees/Management: The capital raise provides working capital, which can support ongoing operations and strategic initiatives, potentially stabilizing employment and growth prospects.
• Creditors: The capital raise improves the company's liquidity and financial position, which could be viewed positively by creditors, but the senior ranking of Series B Preferred Stock in liquidation means it sits above common equity in the capital structure.

Next Steps

• Company to use reasonable efforts to obtain stockholder approval for the full issuance of Conversion Shares in accordance with Nasdaq Listing Rule 5635(d) within 60 calendar days after the Initial Closing.
• Company to file an initial registration statement on Form S-3 (or S-1) covering the resale of all Registrable Securities by the Filing Deadline (30 calendar days after Initial Closing Date).
• Company to use best efforts to have the initial registration statement declared effective by the SEC by the Effectiveness Deadline (90 calendar days after Initial Closing Date).
• Company to maintain the effectiveness of the registration statement during the Registration Period.
• Company to make mandatory monthly dividend payments on Series B Preferred Stock starting October 1, 2025.
• Company may issue and sell up to 10,000 additional shares of Series B Preferred Stock in future closings.

Key Dates

Recommendation

While the capital raise provides essential working capital and demonstrates investor confidence in Nocera's ability to secure funding, the terms of the Series B Preferred Stock introduce significant financial obligations and risks. The 9.0% annual dividend and numerous mandatory redemption triggers, particularly those tied to stock price and market capitalization, could place considerable strain on the company's finances and lead to substantial dilution or forced repurchases under adverse conditions. The discount on the preferred stock purchase price also suggests a less favorable financing environment. Investors should 'hold' to monitor the company's ability to manage these obligations, achieve stockholder approval for conversion, and execute its business plan effectively without triggering the downside protection clauses for the preferred shareholders. The high risk associated with the preferred stock's terms offsets the immediate benefit of the capital infusion.

Keywords

Nocera Inc, NCRA, SEC Filing, 8-K, Securities Purchase Agreement, Preferred Stock, Series B Convertible Non-Voting Preferred Stock, Capital Raise, Institutional Investor, Equity Financing, Convertible Securities, Registration Rights, Corporate Governance, Dilution, Dividends, Redemption, Nasdaq Listing Rule 5635(d), Risk Factors